8-K ·Filed Jul 24, 2026

INSP

Inspire Medical Systems, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001609550-26-000041
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts if Carrel's med-tech expertise influences product or M&A direction.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
INSP ▲ +20.70% at T+20d
NEUTRAL call ✓ call won +20.70% · α vs SPY +17.40% · entry $50.93 → $61.47
Next anchor: T+60d in 17d
Latest observation: T+46 +58.42% FF3 residual α
Entry anchored
Jul 24, 03:59 PM ET
via exchange tick
T+1d
+2.04%
call +2.04% · α +1.80%
$51.97
settled 2mo ago
T+5d
-1.41%
call -1.41% · α -2.49%
$50.21
settled 2mo ago
T+20d
+20.70%
call +20.70% · α +17.40%
$61.47
settled 6w ago
T+60d
—
call — · α —
—
in 17d

Price Chart

Loading chart...

Executive Summary

Inspire Medical Systems appointed Michael H. Carrel, CEO of AtriCure (ATRC), to its Board of Directors effective July 20, 2026. This is a routine board addition with no financial impact or strategic change for the company.

Key Facts

  • Michael H. Carrel appointed to Inspire Medical Systems Board of Directors effective July 20, 2026
  • Carrel is President, CEO, and director of AtriCure, Inc. (NASDAQ: ATRC)
  • Carrel will serve as a Class III director until the 2027 Annual Meeting
  • Appointed to Organization and Compensation Committee and Quality, Product Supply and Technology Committee
  • Eligible for standard non-employee director compensation: $55,000 annual cash retainer, $7,500 per committee retainer, $300,000 initial RSU award vesting over 3 years, and $200,000 annual RSU award

Financial Impact

No material financial impact. Director compensation is standard and immaterial relative to company size.

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
36% bullish (25 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001609550-26-000041
Document: 0001609550-26-000041-index-headers.html0001609550-26-000041
Document: 0001609550-26-000041-index.html0001609550-26-000041
Document: 0001609550-26-000041.txt0001609550-26-000041
8 reports for INSP
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for INSP — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
3
NEUTRAL ★ 1/10
$51.97 $61.07▲ +17.51%▲ +14.13%$69.97 (+34.64%)
Jul 24, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$50.93 $61.47▲ +20.70%▲ +17.40%$69.97 (+37.38%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$50.40 $61.69▲ +22.40%▲ +19.50%$69.97 (+38.83%)
Jul 6, 2026
12w ago
Press Release
BEARISH ★ 6/10
$49.45 $50.21▼ −1.54%▼ −2.10%$69.97 (−41.50%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 5/10
$42.70 $51.76▲ +21.22%▲ +19.44%$69.97 (+63.86%)
May 8, 2026
21w ago
144
NEUTRAL ★ 2/10
$43.35 $42.21▼ −2.63%▼ −2.33%$69.97 (+61.41%)
Apr 6, 2026
25w ago
Press Release
NEUTRAL ★ 3/10
$54.14 $54.84▲ +1.29%▼ −7.69%$69.97 (+29.24%)
Mar 20, 2026
28w ago
DEFA14A
NEUTRAL ★ 2/10
$53.72 $56.97▲ +6.05%▼ −3.27%$69.97 (+30.25%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (38h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access